Clinical and economic evaluation of tralokinumab for atopic dermatitis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38950159.
- Also identified by DOI 10.18553/jmcp.2024.30.7.639 and PMC identifier 11217859.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tralokinumab is the first selective interleukin 13 inhibitor approved for moderate to severe atopic dermatitis. This article reports the findings of a comprehensive literature review and extensive economic analysis to assess tralokinumab's safety, effectiveness, and cost. Evidence synthesis involved evaluating comparative effectiveness and conducting economic sensitivity analyses. This review was prepared by the University of Connecticut School of Pharmacy Academy of Managed Care Pharmacy (AMCP) Student Chapter. The student author group won the AMCP National Pharmacy and Therapeutics competition for their tralokinumab product review in March 2023.
Medical subject headings
- Antibodies, Monoclonal
- Cost-Benefit Analysis
- Dermatitis, Atopic